Coronary artery disease (CAD) is the number one disease-related cause of death in the world. It is the main manifestation of atherosclerosis and the most common cause of myocardial infarction (MI).
Inflammation is a well-recognized key driver of CAD. Of note, CAD patients suffer chronic low-grade inflammation even under today’ s optimal treatment (including high-dose statin). This is known to increase the risk of recurrent coronary events, the so-called “residual inflammatory risk”. A key driver in this sustained inflammation are neutrophil. My research focuses on how neutrophil activity affects disease progression in CAD.
